Thank you for your interest! Clinical research connects patients and families with experimental treatments and provides critically needed data to advance the field. The treatments of tomorrow are not possible without it.
See below for more information about the clinical trials and research studies for which we are currently recruiting participants. If you are interested in learning more about participating in these studies, contact foodallergyresearch@choa.org or asthmaresearch@choa.org. You can also call (404) 785-6448 to speak with one of our team members about our research.
Studies currently enrolling or enrolling soon
- Asthma (4+ years): FLAIR – NCT 06052267
- Asthma (12-17 years): ACADIA – NCT 06307665
- Asthma (5-11 years): HORIZON - NCT06023589
- Asthma (12-59 months): Preschool Wheeze
- Peanut Allergy (4+): Alliance (sublingual immunotherapy) – NCT 05440643
- Food Allergy (2-12 years) Psychology Online Survey: PEACH
- Food Allergy (18+ years): Short-Term Linvoseltamab Treatment, on Top of Chronic Dupilumab Treatment, for Adults With Severe Immunoglobulin E (IgE)-Mediated Food Allergy – NCT 06369467
- Asthma: NAVIGATOR (enrollment by invitation only)
Studies that recently completed or are closed to enrollment
Asthma
- Preventing Asthma in High Risk Kids (PARK) (NCT 02570984)
- Oral Bacterial Extract for the Prevention of Wheezing Lower Respiratory Tract Illness (ORBEX) (NCT 02148796)
- Symptom Clusters in Children with Exacerbation-prone Asthma
Allergy
- EPITOPE: Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Young Children 1-3 Years of Age
- POSEIDON: Peanut Oral Immunotherapy Study of Early Intervention for Desensitization (1-3 years of age)
- Study in Pediatric Subjects With Peanut Allergy to Evaluate Efficacy and Safety of Dupilumab as Adjunct to AR101 (Peanut Oral Immunotherapy) - for ages 6-17
- Efficacy and Safety of QGE031 (Ligelizumab) in Patients With Peanut Allergy NCT04984876
- Harmony by Alladapt - NCT04856865 ADP101 for Oral Immunotherapy in Food-Allergic Children and Adults, ages 4 years to young adult
- Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Children and Adults (OUTMATCH)
- Now Enrolling: A Safety and Efficacy Study of PVX108 in Children and Adolescents With Peanut Allergy (NCT 05621317)
- VITESSE by dbv technologies a Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Children 4-7 Years of Age (vitesseallergystudy.com ; NCT05741476)
Eczema
- Adored by Siolta - NCT05003804 Allergic Disease Onset Prevention Study enrolled newborns up to 14 days of life to study STMC-103H, a live biotherapeutic product (LBP) containing a consortium of intestinal bacteria